SHORT- AND LONG-TERM SIDE EFFECTS OF CONCOMITANT CHEMORADIATION TREATMENT FOR CERVICAL CANCER

Abstract: Concomitant chemoradiation (CRT) for locally advanced cervical cancer has become an established treatment based on randomised trials. Major concerns, however, remain over the acute and late toxicity and hence the generalisability of the conclusions of these studies. The study period was from October 2020 to May 2022. A total of 126 patients with Stage IIB to IIIB Cervical Cancer were taken for the study from Patna Medical College Hospital, Patna, Bihar, with consent from the patients. Most patients were of stage IIIB (47.60%) in group A and (54%) in group B. Most patients had parity >5 (68.30%) in group A and (87.30%) in group B. Most patients (58.73%) in group A and (66.66%) in group B completed EBRT within 35 days. Twenty-seven (42.85%) patients in group A and twenty-three (36.50%) patients in group B had a break during EBRT due to toxicity. In conclusion, observation during follow-up after 6 months group A patients, 74.60%, had no evidence of disease; in group B, 76.19% had no evidence of disease or residual disease. In group A, 25.40% had the residual disease; in group B, 24.60% had residual disease.